Literature DB >> 29263264

Enhancing the Thermostability and Immunogenicity of a Respiratory Syncytial Virus (RSV) Live-Attenuated Vaccine by Incorporating Unique RSV Line19F Protein Residues.

Christina A Rostad1,2, Christopher C Stobart1,2, Sean O Todd1,2, Samuel A Molina3, Sujin Lee1,2, Jorge C G Blanco4, Martin L Moore5,2.   

Abstract

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants, and an effective vaccine is not yet available. We previously generated an RSV live-attenuated vaccine (LAV) candidate, DB1, which was attenuated by a low-fusion subgroup B F protein (BAF) and codon-deoptimized nonstructural protein genes. DB1 was immunogenic and protective in cotton rats but lacked thermostability and stability of the prefusion conformation of F compared to strains with the line19F gene. We hypothesized that substitution of unique residues from the thermostable A2-line19F strain could thermostabilize DB1 and boost its immunogenicity. We therefore substituted 4 unique line19F residues into the BAF protein of DB1 by site-directed mutagenesis and rescued the recombinant virus, DB1-QUAD. Compared to DB1, DB1-QUAD had improved thermostability at 4°C and higher levels of prefusion F as measured by enzyme-linked immunosorbent assays (ELISAs). DB1-QUAD was attenuated in normal human bronchial epithelial cells, in BALB/c mice, and in cotton rats but grew to wild-type titers in Vero cells. In mice, DB1-QUAD was highly immunogenic and generated significantly higher neutralizing antibody titers to a panel of RSV A and B strains than did DB1. DB1-QUAD was also efficacious against wild-type RSV challenge in mice and cotton rats. Thus, substitution of unique line19F residues into RSV LAV DB1 enhanced vaccine thermostability, incorporation of prefusion F, and immunogenicity and generated a promising vaccine candidate that merits further investigation.IMPORTANCE We boosted the thermostability and immunogenicity of an RSV live-attenuated vaccine candidate by substituting 4 unique residues from the RSV line19F protein into the F protein of the heterologous vaccine strain DB1. The resultant vaccine candidate, DB1-QUAD, was thermostable, attenuated in vivo, highly immunogenic, and protective against RSV challenge in mice and cotton rats.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  respiratory syncytial virus; vaccines

Mesh:

Substances:

Year:  2018        PMID: 29263264      PMCID: PMC5827408          DOI: 10.1128/JVI.01568-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

2.  Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract.

Authors:  Peter F Wright; Mine R Ikizler; Ricardo A Gonzales; Kecia N Carroll; Joyce E Johnson; Jay A Werkhaven
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.

Authors:  Qing Zhu; Jason S McLellan; Nicole L Kallewaard; Nancy D Ulbrandt; Susan Palaszynski; Jing Zhang; Brian Moldt; Anis Khan; Catherine Svabek; Josephine M McAuliffe; Daniel Wrapp; Nita K Patel; Kimberly E Cook; Bettina W M Richter; Patricia C Ryan; Andy Q Yuan; JoAnn A Suzich
Journal:  Sci Transl Med       Date:  2017-05-03       Impact factor: 17.956

4.  Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

Authors:  Ruth A Karron; Peter F Wright; Robert B Belshe; Bhagvanji Thumar; Roberta Casey; Frances Newman; Fernando P Polack; Valerie B Randolph; Anne Deatly; Jill Hackell; William Gruber; Brian R Murphy; Peter L Collins
Journal:  J Infect Dis       Date:  2005-03-01       Impact factor: 5.226

5.  A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis.

Authors:  Anne L Hotard; Fyza Y Shaikh; Sujin Lee; Dan Yan; Michael N Teng; Richard K Plemper; James E Crowe; Martin L Moore
Journal:  Virology       Date:  2012-10-11       Impact factor: 3.616

6.  A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.

Authors:  Gregory M Glenn; Louis F Fries; D Nigel Thomas; Gale Smith; Eloi Kpamegan; Hanxin Lu; David Flyer; Dewal Jani; Somia P Hickman; Pedro A Piedra
Journal:  J Infect Dis       Date:  2015-08-10       Impact factor: 5.226

7.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

Authors:  B S Graham; G S Henderson; Y W Tang; X Lu; K M Neuzil; D G Colley
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

8.  A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine.

Authors:  T J Kakuk; K Soike; R J Brideau; R M Zaya; S L Cole; J Y Zhang; E D Roberts; P A Wells; M W Wathen
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

9.  The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection.

Authors:  Kate L Stokes; Michael G Currier; Kaori Sakamoto; Sujin Lee; Peter L Collins; Richard K Plemper; Martin L Moore
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

10.  A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation.

Authors:  Christopher C Stobart; Christina A Rostad; Zunlong Ke; Rebecca S Dillard; Cheri M Hampton; Joshua D Strauss; Hong Yi; Anne L Hotard; Jia Meng; Raymond J Pickles; Kaori Sakamoto; Sujin Lee; Michael G Currier; Syed M Moin; Barney S Graham; Marina S Boukhvalova; Brian E Gilbert; Jorge C G Blanco; Pedro A Piedra; Elizabeth R Wright; Martin L Moore
Journal:  Nat Commun       Date:  2016-12-21       Impact factor: 14.919

View more
  7 in total

1.  Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2.

Authors:  Mariana F Tioni; Robert Jordan; Angie Silva Pena; Aditya Garg; Danlu Wu; Shannon I Phan; Christopher M Weiss; Xing Cheng; Jack Greenhouse; Tatyana Orekov; Daniel Valentin; Swagata Kar; Laurent Pessaint; Hanne Andersen; Christopher C Stobart; Melissa H Bloodworth; R Stokes Peebles; Yang Liu; Xuping Xie; Pei-Yong Shi; Martin L Moore; Roderick S Tang
Journal:  NPJ Vaccines       Date:  2022-07-29       Impact factor: 9.399

2.  Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.

Authors:  Miaoge Xue; Rongzhang Wang; Olivia Harder; Phylip Chen; Mijia Lu; Hui Cai; Anzhong Li; Xueya Liang; Ryan Jennings; Krista La Perle; Stefan Niewiesk; Mark E Peeples; Jianrong Li
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

Review 3.  Attenuation of Human Respiratory Viruses by Synonymous Genome Recoding.

Authors:  Cyril Le Nouën; Peter L Collins; Ursula J Buchholz
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

Review 4.  Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Larry J Anderson
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

5.  Mutation of Respiratory Syncytial Virus G Protein's CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells.

Authors:  Binh Ha; Tatiana Chirkova; Marina S Boukhvalova; He Ying Sun; Edward E Walsh; Christopher S Anderson; Thomas J Mariani; Larry J Anderson
Journal:  Vaccines (Basel)       Date:  2019-07-19

6.  High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers.

Authors:  Iván Del Moral-Sánchez; Rebecca A Russell; Edith E Schermer; Christopher A Cottrell; Joel D Allen; Alba Torrents de la Peña; Celia C LaBranche; Sanjeev Kumar; Max Crispin; Andrew B Ward; David C Montefiori; Quentin J Sattentau; Kwinten Sliepen; Rogier W Sanders
Journal:  NPJ Vaccines       Date:  2022-02-28       Impact factor: 9.399

7.  Dynamical Differences in Respiratory Syncytial Virus.

Authors:  Ryan Heumann; Carly Duncan; Christopher C Stobart; Scott Kaschner
Journal:  Bull Math Biol       Date:  2021-11-30       Impact factor: 1.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.